Published Date: January 10, 2026
A groundbreaking treatment known as AmblyoFix is now under evaluation for its potential to treat unilateral amblyopia in children. Led by Eyesight Electronics and Al Watany Eye Hospital, this new approach focuses on binocular digital therapy as an alternative to conventional treatment options.
What changed?
The AmblyoFix binocular digital therapy is currently recruiting participants for clinical evaluation. Unlike traditional approaches that rely on monocular vision exercises, this innovative behavioral therapy leverages digital tools to engage both eyes simultaneously, aiming to improve neural processing and visual acuity in children diagnosed with amblyopia.
Details of the clinical trial
Who is conducting the study?
This trial is sponsored by Eyesight Electronics in collaboration with Al Watany Eye Hospital. Both organizations are known for their commitment to advancing ophthalmic research and developing state-of-the-art treatments.
What is the intervention?
The intervention involves the use of AmblyoFix, a medical device employing binocular digital therapy. Unlike patching, which isolates the stronger eye, AmblyoFix promotes simultaneous use of both eyes, encouraging neural improvement through guided digital exercises.
Eligibility criteria for children
The trial targets children diagnosed with unilateral amblyopia, offering them the opportunity to explore a potentially more effective treatment pathway. Recruitment is actively ongoing, allowing eligible families to participate in the study and benefit from this novel approach.
Who is affected?
AmblyoFix’s evaluation represents hope for clinical teams, parents, and children dealing with unilateral amblyopia. If proven effective, it could reshape treatment standards, replacing traditional patching methods that are often uncomfortable and have inconsistent compliance rates.
FAQs
1. What is AmblyoFix?
AmblyoFix is a digital therapy device designed to treat unilateral amblyopia. It uses behavioral techniques to improve binocular vision.
2. How does AmblyoFix differ from patching?
Unlike patching, which isolates the stronger eye, AmblyoFix encourages simultaneous use of both eyes through digital exercises.
3. Is recruitment still open?
Yes, recruitment for the clinical trial is ongoing.
4. What is the intended outcome of this therapy?
The primary goal is to enhance neural processing and visual acuity in children with unilateral amblyopia.
Conclusion
The clinical trial evaluating AmblyoFix marks a significant step forward in amblyopia treatment. As recruitment progresses, the trial could offer promising insights that will impact clinical practices worldwide. Stakeholders in the ophthalmology field should monitor the outcomes closely.
Disclaimer
This information is for professional reference only and does not constitute legal or medical advice. Readers should consult appropriate regulatory professionals or healthcare providers for individual concerns.
Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07323953?term=medical+device